REACTION, NCT03610711: (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer |
|
|
| Active, not recruiting | 1/2 | 21 | US | Nivolumab, Optivo, Relatlimab, anti-LAG3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Gastroesophageal Cancer, Immune Checkpoint Inhibition | 12/25 | 12/25 | | |
